These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27609360)

  • 1. Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients.
    Zaharenko L; Kalnina I; Geldnere K; Konrade I; Grinberga S; Židzik J; Javorský M; Lejnieks A; Nikitina-Zake L; Fridmanis D; Peculis R; Radovica-Spalvina I; Hartmane D; Pugovics O; Tkáč I; Klimčáková L; Pīrāgs V; Klovins J
    Eur J Endocrinol; 2016 Dec; 175(6):531-540. PubMed ID: 27609360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
    Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
    Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
    Kashi Z; Masoumi P; Mahrooz A; Hashemi-Soteh MB; Bahar A; Alizadeh A
    Diabetes Res Clin Pract; 2015 Apr; 108(1):78-83. PubMed ID: 25662675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT.
    Out M; Becker ML; van Schaik RH; Lehert P; Stehouwer CD; Kooy A
    Pharmacogenomics; 2018 Jun; 19(8):715-726. PubMed ID: 29790415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of metformin: variability due to polymorphisms of organic cation transporters.
    Zolk O
    Ann Med; 2012 Mar; 44(2):119-29. PubMed ID: 21366511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
    Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
    J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.
    Dujic T; Zhou K; Yee SW; van Leeuwen N; de Keyser CE; Javorský M; Goswami S; Zaharenko L; Hougaard Christensen MM; Out M; Tavendale R; Kubo M; Hedderson MM; van der Heijden AA; Klimčáková L; Pirags V; Kooy A; Brøsen K; Klovins J; Semiz S; Tkáč I; Stricker BH; Palmer C; 't Hart LM; Giacomini KM; Pearson ER
    Clin Pharmacol Ther; 2017 Jun; 101(6):763-772. PubMed ID: 27859023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
    Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
    Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of OCT3 and MATE2 Genetic Polymorphisms in Poor Response to Metformin in Type 2 Diabetes Mellitus.
    Naem AAA; Al-Terehi MN; Ghafil FA; Ataya FS; Batiha GE; Alexiou A; Papadakis M; Welson NN; Hadi NR
    Endocrinol Diabetes Metab; 2024 Sep; 7(5):e486. PubMed ID: 39086121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
    Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS
    Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
    Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
    Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism in human organic cation transporters and metformin action.
    Takane H; Shikata E; Otsubo K; Higuchi S; Ieiri I
    Pharmacogenomics; 2008 Apr; 9(4):415-22. PubMed ID: 18384255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
    Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
    J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
    Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
    Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes.
    Liang H; Xu W; Zhou L; Yang W; Weng J
    Diabet Med; 2017 Jul; 34(7):987-992. PubMed ID: 28321905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine.
    Wang ZJ; Yin OQ; Tomlinson B; Chow MS
    Pharmacogenet Genomics; 2008 Jul; 18(7):637-45. PubMed ID: 18551044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin.
    Li S; Xu B; Fan S; Kang B; Deng L; Chen D; Yang B; Tang F; He Z; Xue Y; Zhou JC
    Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1107-1117. PubMed ID: 36065506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin.
    Chen EC; Liang X; Yee SW; Geier EG; Stocker SL; Chen L; Giacomini KM
    Mol Pharmacol; 2015 Jul; 88(1):75-83. PubMed ID: 25920679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin.
    Li Q; Liu F; Zheng TS; Tang JL; Lu HJ; Jia WP
    Acta Pharmacol Sin; 2010 Feb; 31(2):184-90. PubMed ID: 20139901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.